Aclaris halves headcount, banks on next mid-stage readout after clinical setbacks tanked shares

A month af­ter re­veal­ing that its lead can­di­date had hit a dead end in in­flam­ma­to­ry dis­eases, Aclaris Ther­a­peu­tics will cut just un­der half of its work­force to save cash while wait­ing for its new de­vel­op­ment plans to bear fruit.

About 46% of its em­ploy­ees will be laid off over the next six months, Aclaris said in a Tues­day up­date. The biotech had 105 em­ploy­ees as of De­cem­ber 31, 2022, and per a new fil­ing, the lay­offs are ex­pect­ed to in­cur about $5 mil­lion to $5.3 mil­lion in costs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.